UC Berkeley’s cell therapy developer has filed for an initial public offering.

AbbVie, Novartis, Corteva and Heritage Medical Systems will have an opportunity to exit the cell therapy developer through an initial public offering.

Sirnaomics, which counts Walvax Bio, China Resources Group and Charoen Pokphand Group as existing investors, has raised series E funding to advance its drug development activities.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Novo-backed Procept BioRobotics has secured series G funding to further commercialise its surgical robotic system.

Lilly Asia Ventures is among the participants in a series A round for the lung cancer drug developer that could potentially reach $150m.

GlaxoSmithKline, Johnson & Johnson and DaVita HealthCare Partners had invested in the medical device provider before it floated above its range.

Ipreo and Barclays-backed financial communication technology developer OpenExchange raised $23m while Blue Cross Blue Shield, Optum and Marshfield Clinic are set to exit Contessa Health.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.